STOCK TITAN

SOL Global Investments Corp - SOLCF STOCK NEWS

Welcome to our dedicated news page for SOL Global Investments (Ticker: SOLCF), a resource for investors and traders seeking the latest updates and insights on SOL Global Investments.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOL Global Investments's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOL Global Investments's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
management
SOL Global Investments Corp

OTC:SOLCF

SOLCF Rankings

SOLCF Stock Data

2.32M
45.08M
17.56%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Toronto

About SOLCF

scythian is a pharmaceutical development company currently undertaking pre-clinical testing at the university of miami on a combination drug therapy for the treatment of traumatic brain injury ("tbi") and concussion. tbi happens when there is a major impact to the head or subjected to accelerative forces. it frequently results in both initial damage from the impact itself and significant subsequent damage from inflammation and the body's own immune response. a significant amount of brain injury occurs from the inflammatory and immune response. scythian’s pharmaceutical approach aims to reduce both the inflammation and the immune response by using a combination of two drugs as the acute emergency room or post injury treatment. a broad based u.s. provisional patent application has been filed utilizing drug combinations which affect the endocannabinoid pathway to treat concussions. scythian's second business line is its application to become a licensed producer of medical marijuana in can